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Abstract
Marijuana use during pregnancy has dramatically increased in recent years, driven in part
by the increasing legalization of marijuana for medicinal and recreational
use. However, the impact of prenatal exposure to marijuana on a developing fetus is not
clear. Previous studies examining this effect have been limited by polysubstance
use during pregnancy and confounding factors that make data
interpretation challenging. In this study, we propose a prospective cohort study that will
address the limitations of prior studies and measure the association between prenatal
marijuana exposure and adverse neonatal outcomes. Strict exclusion criteria will exclude
women with tobacco, alcohol or other illicit drug use while pregnant. These insights will
improve currently available research and enhance evidence-based practice
recommendations for women who are pregnant or may become pregnant.

vi

CHAPTER 1: INTRODUCTION
1.1 Background
Across the United States (US), laws surrounding marijuana are rapidly changing. As
of July 2020, thirty-three states and the District of Columbia (D.C.) have legalized
marijuana for medicinal use.1 Thirteen of these thirty-three states passed new laws in the
past five years alone,2 with eleven states and D.C. additionally legalizing marijuana for
recreational use.1 Although specific laws vary by state, generally marijuana can now be
used recreationally without a medical prescription. Individuals cannot be ticketed,
arrested, or convicted for consumption if they adhere to their state laws on required age,
location, and amount.3 In fifteen other states, marijuana has been decriminalized.1
Decriminalization reduces penalties for individuals that possess marijuana for personal
consumption. Rather than criminal prosecution or arrest, possession is treated as a minor
infraction similar to a traffic violation.3 This recent rise in legalization and
decriminalization gives reason to believe other states may adopt similar laws in the near
future.
Increasing public support for legalization has facilitated the passage of new state
laws. In 1969, Gallup, a Washington D.C. based analytics company, found public support
for legalization was 12%.4 By 2018, support had dramatically increased to 66%.4
Advocates believe marijuana should be legalized because it is a “relatively harmless
herb” that is natural and safe for consumption.5 Consumers who support this claim
believe increasing legalization affirms marijuana safety. This belief strikes controversy in
the public health realm as healthcare providers question the true safety of the drug.
Presently, marijuana has not been tested for safety or effectiveness. The US Food and
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Drug Administration (FDA) has not approved marijuana for any indication and warns
consumers that untested drugs can have unidentified consequences.6 If new state laws
increase marijuana availability and use, then more patients may be at risk for unknown
health consequences.
In particular, one vulnerable population that may be at increased risk is neonates
exposed to marijuana in utero. This population is often overlooked by advocates as
neonates are not direct buyers or consumers. However, marijuana has historically been
the most commonly used illicit drug during pregnancy.7 Expanding legislation has caused
considerable concern for maternal-fetal medicine as rates of consumption are rising
among pregnant women. According to the US National Survey on Drug Use and Health,
marijuana use during pregnancy more than doubled between 2002 and 2017.8 During this
time, the percentage of women reporting past-month usage increased from 3.4% to 7%.8
This increase was among women that knew they were pregnant. Researchers are worried
legalization is creating a false perception of safety for pregnant women.9
Surveys to ascertain women’s perspectives on marijuana use during pregnancy have
found mixed feelings and varying levels of concern.7 First, it is important to recognize
that the majority of pregnant women do not use marijuana. Non-users commonly report
that it is a dangerous substance that is likely to cause harm to a fetus. These women
believe there is no safe amount of consumption.10 This perspective is considerably
different from pregnant women that support use. These women often view marijuana as
natural and harmless compared to alcohol, tobacco, and other recreational substances
frequently discouraged while pregnant.7 It is also commonly endorsed as an aid in
alleviating morning sickness and appetite changes.7 Various reports have found
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employees of marijuana dispensaries recommend use to pregnant women experiencing
morning sickness.7 Unfortunately, these recommendations are not evidence-based as no
studies to date have found marijuana to be effective in managing pregnancy-related
nausea and vomiting.7 Among marijuana users that quit during pregnancy, cessation in
the third trimester is often reported. This decision is frequently made as a result of fear of
drug screening at birth and being reported to child protective services.7 Harm reduction is
not their primary motivation.7
Varying perspectives pose a challenge for women seeking guidance during
pregnancy. Although the majority of women inherently think marijuana is unsafe and will
discourage use, opposing perspectives from peers, online resources, and discussion
boards are on the rise. Further complicating the decision-making process is the
uncertainty that exists in current research. Numerous studies show an increased risk of
adverse neonatal outcomes while a comparable number of studies show no increased risk.
Incongruent data makes it difficult for women to determine the true impact marijuana use
may have on fetal development. This challenge is leaving women frustrated with the
conflicting information available.7
Incongruent research has also hindered the development of evidence-based practice
recommendations. In October of 2017, the American College of Obstetricians and
Gynecologists (ACOG) released a committee opinion addressing the current issue. This
report emphasized the unknown fetal consequences, the increasing use among pregnant
women, and the need for further research. ACOG states ”high-quality studies regarding
the effects of marijuana and other cannabis products on pregnancy and lactation are
needed.”11 Until neonatal outcomes become more clear, the official ACOG
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recommendation for providers is to encourage patients to abstain from all marijuana use
while pregnant.11 A similar statement from The American College of Physicians was
released the following year. Addressing the inconsistent information available, it was
stated that, “An urgent need exists to understand the effects of prenatal marijuana
exposure, because it may continue to rise in conjunction with the growing acceptance,
accessibility, and spread of legalization in the United States.”12 More research is urgently
needed to identify risk during pregnancy and to enhance evidence-based practice
recommendations.

1.2 Statement of the Problem
Although diverse patient populations may be at increased risk for unknown health
consequences associated with marijuana use,13 neonates exposed in utero are particularly
vulnerable. This population is exposed during critical periods of physical and cognitive
development,14 which may increase adverse neonatal outcomes at birth. Prior studies
have demonstrated an increased risk of low birth weight, prematurity, lower Apgar
scores, and the need for intensive care after delivery. However, despite evidence in
support of a positive association, study limitations have caused uncertainty.
One of the most significant limitations is the study population. Existing research is
profoundly based on patients with polysubstance use. Some studies have reported
polysubstance use as high as 50% in populations of women using marijuana during
pregnancy.15 Pregnant women have reported using tobacco, alcohol, cocaine, heroin,
ecstasy, opiates, and other substances in addition to marijuana.16-18 It is difficult to isolate
marijuana’s effect in the presence of other substances with known adverse neonatal
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outcomes. For example, fetal alcohol spectrum disorders have been discussed at length in
the literature,19 as well as the negative effects of prenatal opioid and tobacco exposure.20
With polysubstance use, it is challenging to determine whether an association resulted
from one substance, or is an interaction between multiple. To fully attribute an effect to
marijuana, it must be analyzed in isolation.
A second main limitation in current research is sample size. Small sample sizes
limit statistical power and the strength of an association. This limitation is often a result
of polysubstance use. Many studies have struggled to identify a patient population using
exclusively marijuana.21 Consequently, women with alcohol, tobacco, or other drug use
during pregnancy are often included in sample populations.22 This increases the difficulty
in data analysis and interpretation of results. Larger sample sizes of independent
marijuana use are needed to analyze the specific association with adverse neonatal
outcomes.16
Although a randomized control trial would provide results with the greatest certainty,
it is unethical to assign pregnant women to an exposure that may cause harm. That would
go against the current ACOG recommendation and potentially endanger fetal
development. A new prospective cohort study addressing past limitations will improve
currently available research. This will fill the gap in literature and enhance our
understanding of the true association between prenatal marijuana use and adverse
neonatal outcomes.
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1.3 Goals and Objectives
Consequently, we aim to determine the association between prenatal marijuana
exposure and neonatal outcomes. More specifically, we will examine whether marijuana
use independently affects neonatal outcomes at birth. The primary adverse outcome of
measure will be low birth weight. Women that use tobacco, alcohol, or other illicit
substances during pregnancy will be excluded from both the exposure and non-exposure
group. A comprehensive recruitment process will identify women meeting strict criteria
in a sample size large enough to adequately power our study.

1.4 Hypothesis
We hypothesize that the proportion of neonates less than 2,500 grams at birth will
be statistically significantly higher among women that use marijuana during pregnancy
compared to the proportion of neonates less than 2,500 grams at birth among women that
do not use marijuana during pregnancy.

1.5 Definitions
Neonate – newborn less than 28 days old
Low birth weight – body weight less than 2,500 grams at birth
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CHAPTER 2: LITERATURE REVIEW
2.1 Introduction
With assistance from the Yale School of Medicine librarians, we conducted a
systematic search of the literature in July 2019, December 2019, and April 2020. Ovid,
PubMed, Scopus, and The Cochrane Library were searched using the following
keywords: cannabis, marijuana, low birth weight, and pregnancy outcome. First, a broad
search was conducted using ((cannabis) OR (marijuana) AND pregnancy outcome).
Articles were selected with relevant titles and abstracts. To narrow the search and ensure
the selection of articles more specific to the primary outcome, we searched ((marijuana)
OR (cannabis) AND low birth weight). Articles were selected from 1980 to present. We
also chose resources from the reference lists of studies selected through the initial
systematic search. This review identified prospective cohort, retrospective cohort, casecontrol, and cross-sectional studies, as well as secondary analyses of data, meta-analyses
and literature reviews. Each selection was analyzed to identify limitations and determine
how our study can best address gaps in research.

2.2 Marijuana Exposure in Utero
In the late 1900s, there was a dramatic rise in research on prenatal exposures and
neonatal outcomes.1 Research began to show that relatively harmless substances for a
mother could be teratogenic.1 Since this time, numerous studies have specifically
examined the impact of marijuana use during pregnancy. From this research, ways in
which marijuana may alter fetal development have been identified.
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Delta-9-tetrahydrocannabinol, commonly known as THC, is the principal
psychoactive ingredient in marijuana. THC and its metabolites can cross the placenta and
be transferred to a fetus in utero.2 This transfer is facilitated by the human
endocannabinoid system which is responsible for maintaining homeostasis,3 and
processes of pain, memory, appetite, metabolism, stress, and immunity.4,5 The two main
receptors, cannabinoid receptor type 1 (CB1) and cannabinoid receptor type 2 (CB2), are
present in the placenta and fetal brain beginning in early development.6,7 These receptors
bind endocannabinoids,4 which are natural cannabis-like molecules produced in the
body.8 Consequently, exogenous cannabinoids such as THC can bind these receptors to
affect body processes.4 Furthermore, THC can modify placental genes for cell
morphology, growth, ion exchange and apoptosis,7 which can impair support for a
growing fetus.1
Fetal support may also be impaired by carbon monoxide (CO) exposure when
marijuana is smoked. This exposure reduces blood supply to the placenta and fetal
oxygenation.9,10 CO from marijuana can reach blood levels five times higher than
cigarettes.11 Higher levels occur from a greater depth of inhalation, larger puff volumes,
and longer time holding breath with inspiration.12 These techniques increase the delivery
of marijuana to the body and the amount of THC that can be transferred to a fetus.
Further increasing marijuana exposure is its ability to be stored in a mother’s body.
THC is fat-soluble and can be deposited in body fat after consumption.13 These stores
continuously release metabolites into the bloodstream,14 prolonging exposure to a fetus.15
Although a mother may stop marijuana use during pregnancy, her fetus may still be
exposed for weeks after cessation.
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Finally, marijuana may increase exposure to other toxins. Marijuana contains the nonpsychoactive ingredient cannabidiol (CBD). CBD can increase the permeability of the
placenta,16 causing a breakdown of the natural barrier between maternal and fetal
circulations. This breakdown can increase fetal exposure to other harmful substances that
may be present in the mother’s body.17

2.3 Prenatal Marijuana Use and Adverse Neonatal Outcomes
Prior studies analyzing prenatal marijuana exposure have measured various
neonatal outcomes at birth. Commonly measured outcomes include low birth weight
(LBW), preterm birth (PTB), small for gestational age (SGA), lower Apgar scores, and
neonatal intensive care unit (NICU) admission. Research shows marijuana use during
pregnancy can increase the risk for all five adverse outcomes.
Low birth weight is the primary outcome of this study because of its strong
association with morbidity and mortality.18 Neonates less than 2,500 grams at birth are at
increased risk for respiratory distress syndrome, intraventricular hemorrhage, patent
ductus arteriosus, necrotizing enterocolitis, retinopathy of prematurity, jaundice, and
infections during the newborn period.19 Research has also shown an increased risk of
neurosensory impairments, decreased intelligence quotient (IQ), and lower educational
achievements later in life.20 These complications can occur in LBW neonates that are
born preterm or full term. Many studies have found an increased risk of LBW among
neonates exposed to marijuana in utero. For instance, a retrospective cohort study in 2012
looked at 24,874 births between 2000 and 2006 at Mater Mothers’ Hospital in Brisbane,
Australia. Researchers found neonates born to marijuana users were more than twice as
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likely to be of low birth weight (OR 2.4, 95% CI 2.0-2.9).21 This association remained
statistically significant after controlling for maternal age, parity, ethnicity, weight,
cigarette use, alcohol consumption, and illicit drug use (aOR 1.7, 95% CI 1.3-2.2).21 In
2018, researchers looked at the Colorado Pregnancy Risk Assessment Monitoring System
from 2014 to 2015. In total, 3,207 deliveries were analyzed. Prenatal marijuana use was
associated with a 50% increased likelihood of LBW (aOR 1.5, 95% CI 1.1-2.1) after
adjustment for prenatal tobacco use, maternal age, race, ethnicity, and level of
education.22 In 2019, a retrospective cohort study looked at 5,343 women between 2011
and 2016 at two main obstetric hospitals in Washington State. After controlling for
cigarette, alcohol, and illicit drug use, marijuana use increased the likelihood of having a
low birth weight neonate by 42% (aOR 1.42, 95% CI 1.01-2.01).23
In addition to LBW, preterm birth is also associated with morbidity and
mortality.24 Neonates born before 37 weeks’ gestation are at increased risk for
intraventricular hemorrhage, neurologic impairment, necrotizing enterocolitis,
retinopathy of prematurity, and bronchopulmonary dysplasia.25 One of the earliest reports
of prenatal marijuana use and preterm birth was in 1983. From 1975 to 1981, researchers
prospectively analyzed 7,301 births at Queen Victoria Hospital in East Grinstead,
England. Results showed marijuana use more than once a week during pregnancy was
significantly associated with preterm birth (P=0.0002).26 A later report from 2016
prospectively looked at spontaneous preterm birth in 5,588 deliveries. Spontaneous
preterm birth was defined as delivery before 37 weeks’ gestation that was not a result of
obstetric or medical intervention. Women were selected from centers in Australia, New
Zealand, Ireland, and the United Kingdom between 2004 and 2011 using the international
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SCOPE (Screening for Pregnancy Endpoints) study. Researchers found that prenatal
marijuana use was associated with spontaneous preterm birth independent of cigarette use
(aOR 2.28, 95% CI 1.49-3.60).27 More recently in 2019, a retrospective cohort study in
the United States looked at 12,578,557 births between 1999 and 2013. Neonates born to
marijuana users had increased likelihood of preterm birth (aOR 1.40, 95% CI 1.36-1.43)
after controlling for maternal age, race, hospital location or teaching, income, insurance,
multiple pregnancy, pre-existing diabetes mellitus, smoking, hypertension, alcohol
consumption, and other illicit drug use.17
To further assess neonates at birth, gestational age and birth weight can be used to
determine if a newborn is an appropriate size for gestational age. A newborn with a birth
weight for gestational age in <10th percentile is small for gestational age. Neonates that
are SGA may have decreased oxygen levels, hypoglycemia, and difficulty maintaining
body temperature after birth.28 They may also suffer from permanent growth restriction
and increased risk of sudden infant death syndrome.29 The 2012 retrospective analysis at
Mater Mothers’ Hospital in Brisbane, Australia found neonates exposed to marijuana in
utero were more than twice as likely to be in <10th percentile compared to the nonexposure group (aOR 2.2, 95% CI 1.8-2.7).21 In 2019, a retrospective cohort study in
Ontario, Canada analyzed 661,617 deliveries between 2012 and 2017. The marijuana
exposure group had increased odds for being in <10th percentile (RR 1.41, 95% CI 1.36
to 1.45) and <3rd percentile (RR 1.53, 95% CI 1.45-1.61).30 In 2019, another retrospective
cohort study in Canada looked at 243,140 pregnancies in British Columbia between 2008
and 2016. Neonates with prenatal marijuana exposure had increased odds of being in
<10th percentile (OR 1.65, 95% CI 1.50-1.79).10 This association remained statistically
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significant after controlling for maternal age, pre-pregnancy body mass index (BMI),
tobacco use, alcohol use, other substance use, socioeconomic status, race, and ethnicity
(aOR 1.47, 95% CI 1.33-1.61).10
Finally, neonates exposed to marijuana in utero have increased risk of lower
Apgar scores and the need for intensive care after birth. Apgar scores are calculated at
one and five minutes after delivery. This score assesses newborn appearance, pulse,
grimace, activity, and respiration. Each category can receive a score from zero to two
resulting in a total score ranging from zero to ten.31 In 2006, a retrospective cohort study
looked at 416,834 live births between 1998 and 2002 in Southeast, Australia. Neonates
born to marijuana users had significantly lower Apgar scores at five minutes compared to
the non-user group (P<0.001).11 The 2019 retrospective analysis in Ontario, Canada had
Apgar scores as a second measured outcome. Results showed the marijuana exposure
group had an increased risk for Apgar scores less than 4 at five minutes (RR 1.28, 95%
CI 1.13-1.45).30 Results also showed the exposure group had increased risk for neonatal
intensive care unit admission after delivery (RR 1.40, 95% CI 1.36-1.44).30 NICU
admission was also measured in the analysis at Mater Mothers’ Hospital in Brisbane,
Australia. This study showed prenatal marijuana exposure increased odds of NICU
admission (aOR 2.0, 95% CI 1.7-2.4) after controlling for maternal age, parity, ethnicity,
weight, cigarette use, alcohol consumption, and illicit drug use.21

2.4 Inconsistency in Existing Research
Although many studies show a positive association between prenatal marijuana
exposure and adverse neonatal outcomes, a similar number of studies show a null
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association. Illustrating the inconsistency in current research is a meta-analysis from
2016.20 This analysis included one case-control study, one cross-sectional study, and
twenty-two cohort studies conducted between 1982 and 2014. These studies measured
birth weight, low birth weight, gestational age, preterm birth, NICU admission, head
circumference, and neonatal length. Among the 24 studies, each outcome had mixed
results. To illustrate, low birth weight was measured in seven studies. Two studies
reported a positive association while five reported a null association. In nine studies
measuring preterm birth, three showed a positive association while six demonstrated a
null association. Four studies measured NICU admission after delivery. Three reported a
positive association while one reported a null association. The remaining outcomes of
birth weight, gestational age, head circumference, and neonatal length similarly had
inconsistent findings. Differences in specific findings across studies are likely due to
variations in sample size, substance use during pregnancy, sample demographics, data
collection, and statistical analysis. Limitations in these areas will be discussed in detail
through the remainder of this review.

2.5 Polysubstance Use During Pregnancy
Women that use marijuana during pregnancy frequently report polysubstance use.
Most commonly, alcohol and tobacco are reported in addition to marijuana.32-34 Other
substances such as cocaine, heroin, phencyclidine (PCP), and lysergic acid diethylamide
(LSD) are reported with less frequency.35 Since polysubstance use is common, studies
must include a thorough substance use history in sample populations. This is particularly
important to identify substances known to cause adverse neonatal outcomes. For
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example, it is well established that alcohol and tobacco exposure during pregnancy
increase neonatal risk for preterm birth, low birth weight, and being small for gestational
age.20 Thus, these substances are major confounding factors in studies analyzing the
association between prenatal marijuana use and these adverse neonatal outcomes.
Although studies have routinely controlled for these confounders in data analysis,
researchers have found data interpretation challenging.2 It is difficult to analyze the effect
of one substance in the presence of others. Multiple substances may have a synergistic
effect,36 and an individual drug may not be appropriately adjusted for in the statistical
analysis. Consequently, researchers have found it difficult to fully attribute an outcome to
marijuana when other substances are present.10
Despite the challenge polysubstance use creates for data analysis, polysubstance
users have consistently been included in sample populations.20,37,38 These women are
often included due to difficulty in finding populations that use marijuana in isolation. A
retrospective cohort study in 2013 highlights this difficulty.36 In this study, researchers
found single drug use during pregnancy to be relatively unusual. In their sample, 96% of
subjects used tobacco in addition to an illegal drug while pregnant. Further highlighting
the difficulty is the meta-analysis from 2016.20 Participants were included in the analysis
if marijuana was the only reported illicit drug during pregnancy. For instance, cocaine or
barbiturate use were exclusion criteria. However, alcohol and tobacco use were not.
Authors stated “owing to low numbers of studies that account for concurrent cannabis,
alcohol and tobacco use, studies reporting outcomes of in utero exposure to cannabis in
the presence of smoking tobacco and consuming alcohol were included.”20

22

Analyses of women using only marijuana during pregnancy are relatively rare.
Studies that have identified pregnant women without polysubstance use have
subsequently been limited by sample size. Small sample sizes limit study power and
create a large margin for statistical error. One study with this limitation is a retrospective
cohort analysis in 2016. This study found exclusive marijuana use during pregnancy was
not associated with adverse neonatal outcomes such as low birth weight and preterm
birth.39 The sample population consisted of 12,069 women that were analyzed between
2011 and 2015.39 Although the total study population was large, only 106 women were
marijuana users. Furthermore, 48 women used tobacco in addition to marijuana. This
created a final sample of only 58 women with exclusive marijuana use during pregnancy.
Therefore, the sample was too small, and the study was underpowered. A second
retrospective cohort study analyzed 6,468 women between 2008 and 2011.13 This
analysis reported mixed results, showing a positive association for NICU admission and
small for gestational age but a null association for preterm birth. The sample size in this
study had a larger population of pregnant women without polysubstance use but it was
too small to adequately power the study.40 This final sample consisted of only 153
women with exclusive marijuana use during pregnancy.
Polysubstance use and small sample size are significant limitations in current
research. Existing studies have not used sampling methods that specifically exclude
women with tobacco, alcohol, and illicit drug use. Polysubstance users are included in
data collection and later adjusted for in the statistical analysis. Consequently, samples of
pregnant women without polysubstance use have been too small within total study
populations. To reach adequate statistical power, future studies must recruit a larger

23

sample of women with exclusive marijuana use during pregnancy. Until this is
accomplished, the association will remain uncertain.

2.6 Confounding Variables
2.6.1 Lifestyle Factors
Exercise and body weight are both associated with marijuana use and neonatal
outcomes at birth. First, marijuana acts as a depressant in the human body.41 It can slow
normal body processes and reduce physical activity by changing how the brain sends and
receives signals.41 During pregnancy, regular aerobic and strength-conditioning exercises
are frequently encouraged.42 In uncomplicated pregnancies, moderate exercise for 20-30
minutes on most or all days of the week can improve fitness, aid in weight management,
and reduce the risk of gestational diabetes.42 Pregnant women that do not exercise, or
have reduced physical activity, may not achieve these benefits.
Second, marijuana can affect body weight and body mass index by altering an
individual’s diet. Marijuana use can lead to irregular eating patterns and poor nutritional
intake.41 Body mass index measures body fat through a calculation using height and
weight.43 The four BMI categories are underweight (<18.5), normal weight (18.5-24.9),
overweight (25-29.9), and obese (30 or higher).43 Pre-pregnancy BMI is an important
measure to assess risk during pregnancy. Women that are underweight, overweight, or
obese at conception have a higher risk for adverse maternal and neonatal outcomes
compared to women of healthy weight. For example, women with a BMI <18.5 are at
increased risk for preterm birth and having a neonate with a LBW.44 Women with a BMI
over 25 are at increased risk for preterm birth, high blood pressure, gestational diabetes
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and having a baby that is large for gestational age (LGA).45 A large for gestational age
neonate has a birth weight for gestational age in >90th percentile.46
Lastly, pre-pregnancy BMI is used to determine an appropriate gestational weight
gain. Weight gain guidelines are published by the Institute of Medicine (IOM). Following
these guidelines, total weight gain should be 28-40 pounds for underweight women, 2535 pounds for normal-weight women, 15-25 pounds for overweight women, and 11-20
pounds for women that are obese.47 Weight gain outside the recommended ranges can
affect the immediate and future health of a mother and her newborn. Evidence shows
inadequate gestational weight gain can lead to decreased birth weight while excessive
weight gain can lead to increased birth weight.47 Since gestational weight gain, prepregnancy BMI, and exercise can affect neonatal outcomes, prior studies analyzing
prenatal marijuana use have controlled for these factors in the statistical analysis.22,48

2.6.2 Psychosocial Factors
Intimate partner violence, pregnancy intention, and maternal stress can increase
the risk of adverse neonatal outcomes. First, illicit substance use has been associated with
increased rates of physical abuse.49 Women using marijuana or illicit substances during
pregnancy may be at increased risk for intimate partner violence. Physical trauma while
pregnant increases the risk of adverse neonatal outcomes such as preterm birth and low
birth weight.50 To control for intimate partner violence, women are asked to self-report
physical abuse during pregnancy. In 2018, a retrospective cohort study accomplished this
by asking participants, “During your most recent pregnancy, did your husband or partner
push, hit, slap, kick, choke, or physically hurt you in any other way?”51 If women
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responded “yes,” they were classified as having experienced intimate partner violence.
This was then controlled for in the statistical analysis.
In addition to physical trauma, maternal stress is a well-established risk factor for
preterm delivery.52 One source of maternal stress during pregnancy can be pregnancy
intention. Unintended pregnancies are believed to be inherently more stressful than
planned pregnancies. Researchers obtain this information through self-report. The 2018
retrospective analysis that assessed intimate partner violence also assessed pregnancy
intention. Researchers asked women if their current pregnancy was intended or
unintended.51 Another report in 2018 recorded more detailed responses from
participants.22 Women were asked the question “Thinking back to just before you got
pregnant with your new baby, how did you feel about becoming pregnant?” If women
responded with “I wanted to be pregnant later,” “I didn’t want to be pregnant then or at
any time in the future,” or “I wasn’t sure what I wanted,” then they were categorized as
an unintended pregnancy in the statistical analysis.
Overall, many factors can impact maternal stress during pregnancy. It would be
unrealistic to aim to assess every possible factor for each patient. A more realistic
approach is to assess stress levels as a whole. In 2008, a brief version of the Pregnancy
Experience Scale (PES) was studied in a population of 112 pregnant women.53 This scale
measures frequently endorsed pregnancy hassles and uplifts using a 4-point Likert scale.
In this study, the scale was completed five times between 24- and 38-weeks’ gestation.
Results showed the brief version of the scale had internal reliability, test-retest reliability,
and convergent validity comparable to the long version. Researchers concluded the PESBrief is a cost-effective tool to assess stress and emotional valence in pregnancy.53 This
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scale can be used to assess maternal stress when analyzing prenatal marijuana use and
adverse neonatal outcomes.

2.6.3 Prenatal Care
Prenatal care plays an important role in pregnancy management and neonatal
outcomes. Some studies have found women that use marijuana during pregnancy are less
likely to receive adequate prenatal care compared to women that do not use marijuana
during pregnancy.15,54 Regular visits help prevent complications and inform women on
steps to take to promote a healthy pregnancy. These visits are also essential for education
on substance use. To analyze differences in prenatal care between exposure and nonexposure groups, prior studies have used The Kotelchuck Index, also known as the
Adequacy of Prenatal Care Utilization (APNCU) Index.22,55
The Kotelchuck Index uses two independent dimensions to characterize adequacy
of prenatal care utilization: Adequacy of Initiation of Prenatal Care and Adequacy of
Received Services. The first dimension characterizes the adequacy of when prenatal care
began. The second dimension characterizes the adequacy of the total number of visits
received. The expected number of prenatal care visits is determined by the ACOG
recommendation schedule. For uncomplicated pregnancies, ACOG recommends a
prenatal care visit once a month between weeks 4 and 28, twice a month between weeks
28 and 36, and once a week from 36 weeks to birth.56 This information can be used to
calculate adequacy. Depending on the proportion of observed visits to expected visits,
care is classified as inadequate (<50%), intermediate (50-79%), adequate (80-109%) or
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adequate plus (110% or more).57 This index does not assess the quality of care received,
but simply its utilization.

2.6.4 Maternal Data
Maternal characteristics can be mediating factors of both substance use and
neonatal outcomes at birth. These characteristics include age, race, ethnicity, parity, prior
preterm birth, prior low birth weight infant, marital status, education level and income.
Recipient of Medicaid and/or Women, Infants, and Children (WIC) can also be a factor.
WIC is a special supplemental nutrition program that provides supplemental foods,
healthcare referrals and nutrition education to pregnant and postpartum women, infants
and children to the age of five.58
Maternal age can increase the risk of low birth weight and preterm birth. This is
particularly seen among women less than 15 and greater than 35 years old.59,60 Race and
ethnicity can also increase the risk of preterm birth. For example, in 2018 the preterm
birth rate among African American women was 14%. That same year, the rate among
white women was only 9%.61 Women with a prior preterm delivery are also at increased
risk for a subsequent preterm birth.62 Higher maternal parity and a history of a low birth
weight neonate increase the risk for future low birth weight.63 Marital status during
pregnancy may indicate a level of support or an area causing increased maternal stress.
Other characteristics such as education level, income, Medicaid recipient, or WIC support
can be indicators of the resources available to women during pregnancy. These factors
have frequently been cited in prior studies analyzing prenatal marijuana exposure.21-23
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2.7 Relevant Methodology
2.7.1 Marijuana Drug Testing
There are several ways to identify marijuana use in patient populations. Prior
studies have used maternal self-report, urine drug screens (UDS), fetal meconium assays,
maternal serum assays, and the presence of THC in umbilical cord homogenate.
Maternal self-report has been a common method used to identify marijuana use
during pregnancy. Information can be gathered through patient interviews or
questionnaires to obtain immediate results. Prior studies have identified users by asking
drug use directly,27 or using medical record documentation from prenatal care visits.30
Although this is a common method, it is a frequently documented limitation in research
design.38 Reliance on self-report alone is likely to underestimate the true prevalence of
marijuana use in a patient population. Fear of legal consequences or being reported to
child protective services64 can cause reporting bias.51 Regardless of the rationale,
marijuana use is under-reported and risks misclassifying exposure subjects into the nonexposure group. This misclassification can bias results towards the null and potentially
mask a true association.51 Another limitation of self-report is recall bias.38 Patients may
under or overestimate marijuana use when recalling frequency or quantity in weeks prior.
This is a particular concern in studies stratifying participants to analyze dose-dependent
relationships. Without accurate recall, dose-related associations cannot be determined.
Urine drug screens are the most commonly used drug test.65 They are an objective
measure of drug use and are often preferred over subjective self-reports. They are readily
available, easily collected, and non-invasive.65 A commonly cited limitation for UDS is
the timing of testing. For frequent users, marijuana can be detected up to thirty days. For
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less frequent users, a UDS may only be positive for one to three days.66 Time restraints
limit the utility of these tests to frequent or recent users. Patients may wait to take a UDS
until they have passed the positive testing window. To limit this evasion, tests must be
given at regular intervals in high-risk populations.23 This may reduce the risk of
misclassifying users as non-users from a single or infrequent urine drug screen.
One study in 2019 looked at the use of UDS with maternal self-report.67 The
composite study outcome included spontaneous PTB, stillbirth, SGA, and hypertensive
disorders of pregnancy. When using a UDS and maternal self-report to identify the
exposure group (n = 211), marijuana use during pregnancy was associated with increased
risk for the primary composite outcome. When the analysis was repeated using self-report
alone, there was no association. Self-report alone only identified 18 of the 211 (8.5%)
marijuana users in the sample population. The remaining 193 women were identified
from a positive urine drug screen. This change in association emphasizes the role of
biological testing. Without the objective measure, participants were misclassified into the
non-exposure group and the association was biased towards the null.67 Studies that use
subjective self-report alone have a high risk of misclassification.
For newborn drug screening, fetal meconium assay is the current gold standard.65
It is the most sensitive tissue to evaluate fetal drug exposure65 because it contains
metabolic waste products from exposures in utero. Meconium is the first bowel
movement passed by a fetus, typically within the first couple of days after birth. Although
it is the gold standard, it is not without limitation. First, meconium begins to form in the
second trimester of pregnancy when the fetus’ swallowing reflex develops. This
inherently limits meconium assay to exposures in the second or third trimester. Exposures
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during the first trimester will not be present in meconium. Second, meconium may be
passed in utero before a sample can be collected after birth. In utero passage is
unpredictable and limits reliance on meconium assay as a primary testing method. Third,
drugs given during labor can be transferred to a fetus and passed in meconium. This may
alter meconium assays and confound results. Lastly, meconium sampling cannot be
obtained throughout pregnancy. This method can only identify drug exposure after birth.
Umbilical cord testing is similarly limited to post-delivery analysis and is less
frequently used. Challenges arise from obtaining adequate cord samples with variable
timing and location of birth. However, this method has demonstrated strength in objective
testing. A recent analysis in 2017 used umbilical cord homogenate to confirm selfreported drug use.68 Results showed a poor correlation between self-report and objective
testing. This was similar to a study in 1995 that used maternal serum assay to confirm
self-reports. Researchers found that 69% of positive serum assays were from participants
that denied marijuana used in structured interviews.35 Serum assays are more invasive
and less frequently used but further demonstrate the crucial role in biological testing.
They can be used throughout pregnancy and are not limited to post-delivery analysis.
With increasing legalization, accuracy in self-reported drug use may increase.
Decreased fear of legal consequences may allow more pregnant women to share their true
marijuana use history. However, self-report alone remains to have the highest risk for
exposure status misclassification. Future protocols need to incorporate biological testing
in research designs to increase the accuracy of exposure status.
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2.7.2 Marijuana Use Patterns
Currently, there is no reliable way to quantify marijuana use through biological
testing.38 Researchers must rely on self-report to identify frequency or quantity of
consumption. Prior studies analyzing dose-dependent relationships show the quantity of
marijuana is likely a contributing factor in neonatal outcomes.13 For example, a
prospective cohort study in 1984 found marijuana use six or more times per week was
associated with a reduction in length of gestation.69 This was seen after controlling for
nicotine, alcohol, parity, pre-pregnancy weight, and sex of the infant. A later metaanalysis in 1997 evaluated ten studies on neonatal birth weight.34 Results showed
marijuana use at least four times per week was associated with a reduction in mean birth
weight.
Various reports have taken different measures to quantify marijuana use. One of
the earliest reports in 1983 retrospectively asked participants if average marijuana
consumption during pregnancy was occasional, weekly, or daily.70 This was the only
question participants were asked. Researchers recognized this was an early report on
patterns of use and data was poorly quantified. Future studies were encouraged to ask
more detailed questions.
A report three years later at Yale New Haven Hospital assessed frequency with
greater detail. Women were interviewed within a few weeks of their first prenatal care
visit. Marijuana users were asked to report average use. Responses ranged from “less
than once per month but once since pregnant” to “five or more times daily.”71
Participants were then categorized as non-users, occasional users, or regular users.
Occasional use was once per month or less, while regular use was two to three times per
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month or more. These interviews were the only time marijuana use was assessed.
Researchers encouraged future studies to collect data several times during pregnancy.
In 2010, a prospective cohort study collected data on marijuana use in each
trimester.72 Women were asked to report marijuana consumption through the number of
joints used. If women used bowls or blunts, they were asked to convert this amount to an
equivalent number of joints. If they were unsure of the conversion, a bowl would convert
to three joints and a blunt would convert to four joints. This conversion provided a more
detailed report on marijuana smoked during pregnancy. Prior studies have focused on
smoking since it is the most common method of use.73 However, with growing
legalization, marijuana is now more readily available in vapor and oral forms. Future
studies analyzing dose-dependent relationships will have to gather information on these
other forms as well.

2.7.3 Sampling and Recruitment
Prior studies looking at the association between marijuana use and neonatal
outcomes have used consecutive convenience sampling to recruit study participants.14
This was the sampling method in the prospective cohort study at Yale New Haven
Hospital.71 This study used all women presenting for their first prenatal care visit at a
private obstetric or midwifery practice, health maintenance organization or hospital clinic
in New Haven, Connecticut. Women were selected if they intended to deliver at Yale
New Haven Hospital. Using this method, 6,219 women were approached about the study
over two years. In this sample, 3,857 women met the inclusion criteria and 367 were
identified as marijuana users. Consecutive convenience sampling can be used in future
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studies analyzing exclusive marijuana use during pregnancy. Since polysubstance use is
common, approaching all women presenting for a first prenatal care visit can increase the
likelihood of identifying an adequate sample of women with exclusive marijuana use.

2.7.4 Participant Population Criteria
Exclusion criteria from the literature have included multiple birth pregnancies, a
known congenital or chromosomal fetal anomaly, stillbirth, underlying maternal medical
conditions that increase risk during pregnancy, and maternal age <18 due to the need for
parental consent.68,72,74 A woman with a multiple pregnancy is often excluded because it
is a strong risk factor for preterm birth, and more than 50% of women with twins deliver
before 37 weeks’ gestation.75 Specific medical conditions are chronic hypertension or
heart disease requiring medication, diabetes, renal disease, systemic lupus erythematosus,
antiphospholipid syndrome, sickle cell disease, human immunodeficiency virus (HIV),
previous cervical knife cone biopsy, 3 or more pregnancy terminations, and 3 or more
miscarriages. 27,35,48 These conditions put patients at high risk for preterm birth and
having newborns that are SGA.48 Women that use opioids, methadone, amphetamines,
benzodiazepines, and barbiturates during pregnancy have also been excluded to varying
degrees. These substances as well as tobacco, alcohol, and illicit drugs can be
confounding factors for adverse neonatal outcomes. Inclusion criteria have required
participants to have all neonatal outcome variables available after birth.
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2.7.5 Statistical Analysis
A recent study in 2020 reported a positive association between prenatal marijuana
use and low birth weight (OR 1.82, p<0.001).76 In the non-marijuana exposed group
(n=531), 11.5% had a low birth weight. In the marijuana exposed group (n=531), 20.9%
had a low birth weight. This produced an effect size of 9.4%.76 Exposure and nonexposure groups were closely matched for delivery year, delivery hospital, maternal age,
maternal marital status, race, parity, medical insurance, smoking status, alcohol use,
benzodiazepine use, and opioid use. This effect size can be used to calculate sample sizes
in future study designs. As one of the most recent reports on prenatal marijuana use, this
study more closely measures the effect of marijuana at its increased potency compared to
the past.

2.8 Evolving Marijuana Climate
The current climate surrounding marijuana use in the US has significantly
changed over the past 50 years. Not only have there been societal shifts in moral and
legal acceptability,23 but the composition of the drug itself has changed. Advances in
breeding and greenhouse technology have increased marijuana concentrations.77 Potency
is determined by the ratio of THC to CBD. CBD is a non-psychoactive ingredient that
can lessen the effect of THC.78 Thus, increasing CBD in marijuana will lower the ratio of
THC to CBD and decrease overall drug potency. Similarly, decreasing CBD and
increasing THC will increase potency. Since the 1970s, marijuana potency has increased
six to seven-fold.22
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Current research is profoundly based on marijuana use of lower potency,38 in an
era of lower public support, and less frequently reported use. Research relying on selfreports in a time of lower acceptance increases the risk for social desirability bias and
reduces the accuracy of exposure status. New state laws and public acceptance may allow
researchers to better estimate the true prevalence of a patient population. This may reduce
bias and exposure group misclassification. It may also aid in measuring the potential
effects of increased potency. In 2019 alone, six retrospective studies found a positive
association between prenatal marijuana use and adverse neonatal outcomes.10,17,23,30,67,79
In 2020, a newly released study found an increased rate of low birth weight (OR 1.82),
preterm delivery (OR 1.79), NICU admission (OR 1.43), and lower APGAR scores
(p=0.004).76 These more recent reports may represent adverse neonatal outcomes of
present-day marijuana use during pregnancy.

2.9 Conclusion
The current literature on prenatal marijuana use and adverse neonatal outcomes
shows an increased risk for low birth weight, preterm birth, SGA, lower Apgar scores,
and NICU admission. These associations are not, however, unequivocal since a similar
number of studies show a null association. Existing research is limited by polysubstance
use, small sample size, self-reporting bias, recall bias, and inadequate information on
quantification. The inconsistency may also be arising from research conducted in an era
of lower social acceptance, less legalization, and decreased potency. Our proposed
prospective cohort study will fill this current gap in research. We will exclude
participants with polysubstance use, recruit a sample size to reach adequate statistical
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power, use urine drug screens in addition to self-report, and obtain detailed quantification
data to analyze a dose-dependent relationship.

37

Reference List
1.
Huizink AC. Prenatal cannabis exposure and infant outcomes: Overview of
studies. Progress in Neuro-Psychopharmacology and Biological Psychiatry.
2014;52:45-52.
2.
Stickrath E. Marijuana Use in Pregnancy: An Updated Look at Marijuana Use and
Its Impact on Pregnancy. Clin Obstet Gynecol. 2019;62(1):185-190.
3.
De Laurentiis A, Araujo HA, Rettori V. Role of the endocannabinoid system in
the neuroendocrine responses to inflammation. Curr Pharm Des.
2014;20(29):4697-4706.
4.
Maccarrone M, Bab I, Biro T, et al. Endocannabinoid signaling at the periphery:
50 years after THC. Trends Pharmacol Sci. 2015;36(5):277-296.
5.
Alger BE. Getting high on the endocannabinoid system. Cerebrum.
2013;2013:14.
6.
Wu CS, Jew CP, Lu HC. Lasting impacts of prenatal cannabis exposure and the
role of endogenous cannabinoids in the developing brain. Future Neurol.
2011;6(4):459-480.
7.
Khare M, Taylor AH, Konje JC, Bell SC. Delta9-tetrahydrocannabinol inhibits
cytotrophoblast cell proliferation and modulates gene transcription. Mol Hum
Reprod. 2006;12(5):321-333.
8.
Human Endocannabinoid System. UCLA Health.
https://www.uclahealth.org/cannabis/human-endocannabinoid-system. Accessed
March 4, 2020.
9.
Soto E, Bahado-Singh R. Fetal abnormal growth associated with substance abuse.
Clin Obstet Gynecol. 2013;56(1):142-153.
10.
Luke S, Hutcheon J, Kendall T. Cannabis Use in Pregnancy in British Columbia
and Selected Birth Outcomes. J Obstet Gynaecol Can. 2019;41(9):1311-1317.
11.
Burns L, Mattick RP, Cooke M. The use of record linkage to examine illicit drug
use in pregnancy. Addiction. 2006;101(6):873-882.
12.
Wu TC, Tashkin DP, Djahed B, Rose JE. Pulmonary hazards of smoking
marijuana as compared with tobacco. N Engl J Med. 1988;318(6):347-351.
13.
Warshak CR, Regan J, Moore B, Magner K, Kritzer S, Van Hook J. Association
between marijuana use and adverse obstetrical and neonatal outcomes. J
Perinatol. 2015;35(12):991-995.
14.
Zuckerman B, Frank DA, Hingson R, et al. Effects of maternal marijuana and
cocaine use on fetal growth. N Engl J Med. 1989;320(12):762-768.
15.
Conner SN, Carter EB, Tuuli MG, MacOnes GA, Cahill AG. Maternal marijuana
use and neonatal morbidity. American Journal of Obstetrics and Gynecology.
2015;213(3):422.e421-422.e424.
16.
Feinshtein V, Erez O, Ben-Zvi Z, et al. Cannabidiol enhances xenobiotic
permeability through the human placental barrier by direct inhibition of breast
cancer resistance protein: an ex vivo study. Am J Obstet Gynecol.
2013;209(6):573.e571-573.e515.
17.
Petrangelo A, Czuzoj-Shulman N, Balayla J, Abenhaim HA. Cannabis Abuse or
Dependence During Pregnancy: A Population-Based Cohort Study on 12 Million
Births. Journal of Obstetrics and Gynaecology Canada. 2019;41(5):623-630.

38

18.
19.

20.

21.

22.

23.

24.
25.
26.

27.

28.

29.

30.

31.

32.

33.

Phillips DI, Jones A, Goulden PA. Birth weight, stress, and the metabolic
syndrome in adult life. Ann N Y Acad Sci. 2006;1083:28-36.
Low Birthweight. March of Dimes.
https://www.marchofdimes.org/complications/low-birthweight.aspx#. Updated
March 2018. Accessed March 2, 2020.
Gunn JK, Rosales CB, Center KE, et al. Prenatal exposure to cannabis and
maternal and child health outcomes: a systematic review and meta-analysis. BMJ
Open. 2016;6(4):e009986.
Hayatbakhsh MR, Flenady VJ, Gibbons KS, et al. Birth outcomes associated with
cannabis use before and during pregnancy. Pediatric Research. 2012;71(2):215219.
Crume TL, Juhl AL, Brooks-Russell A, Hall KE, Wymore E, Borgelt LM.
Cannabis Use during the Perinatal Period in a State with Legalized Recreational
and Medical Marijuana: The Association between Maternal Characteristics,
Breastfeeding Patterns, and Neonatal Outcomes. Obstetrical and Gynecological
Survey. 2018;73(11):609-611.
Straub HL, Mou J, Drennan KJ, Pflugeisen BM. Maternal Marijuana Exposure
and Birth Weight: An Observational Study Surrounding Recreational Marijuana
Legalization. Am J Perinatol. 2019.
Johnston KM, Gooch K, Korol E, et al. The economic burden of prematurity in
Canada. BMC Pediatr. 2014;14:93.
Ward RM, Beachy JC. Neonatal complications following preterm birth. Bjog.
2003;110 Suppl 20:8-16.
Gibson GT, Baghurst PA, Colley DP. Maternal alcohol, tobacco and cannabis
consumption and the outcome of pregnancy. Aust N Z J Obstet Gynaecol.
1983;23(1):15-19.
Leemaqz SY, Dekker GA, McCowan LM, et al. Maternal marijuana use has
independent effects on risk for spontaneous preterm birth but not other common
late pregnancy complications. Reprod Toxicol. 2016;62:77-86.
Small for Gestational Age. Children’s Hospital of Philadelphia.
https://www.chop.edu/conditions-diseases/small-gestational-age#. Accessed April
4, 2020.
Bailey BA, McCook JG, Hodge A, McGrady L. Infant birth outcomes among
substance using women: why quitting smoking during pregnancy is just as
important as quitting illicit drug use. Matern Child Health J. 2012;16(2):414-422.
Corsi DJ, Walsh L, Weiss D, et al. Association between Self-reported Prenatal
Cannabis Use and Maternal, Perinatal, and Neonatal Outcomes. JAMA - Journal
of the American Medical Association. 2019;322(2):145-152.
What Is the Apgar Score? KidsHealth.
https://kidshealth.org/en/parents/apgar.html. Updated February 2018. Accessed
April 23, 2020.
Coleman-Cowger VH, Oga EA, Peters EN, Mark K. Prevalence and associated
birth outcomes of co-use of Cannabis and tobacco cigarettes during pregnancy.
Neurotoxicol Teratol. 2018;68:84-90.
Bada HS, Das A, Bauer CR, et al. Low birth weight and preterm births: etiologic
fraction attributable to prenatal drug exposure. J Perinatol. 2005;25(10):631-637.

39

34.
35.

36.

37.

38.
39.

40.

41.

42.
43.

44.

45.

46.

47.

48.

English DR, Hulse GK, Milne E, Holman CD, Bower CI. Maternal cannabis use
and birth weight: a meta-analysis. Addiction. 1997;92(11):1553-1560.
Shiono PH, Klebanoff MA, Nugent RP, et al. The impact of cocaine and
marijuana use on low birth weight and preterm birth: A multicenter study.
American Journal of Obstetrics and Gynecology. 1995;172(1 PART 1):19-27.
Black M, Bhattacharya S, Fairley T, Campbell DM, Shetty A. Outcomes of
pregnancy in women using illegal drugs and in women who smoke cigarettes.
Acta Obstet Gynecol Scand. 2013;92(1):47-52.
Conner SN, Bedell V, Lipsey K, Macones GA, Cahill AG, Tuuli MG. Maternal
Marijuana Use and Adverse Neonatal Outcomes: A Systematic Review and Metaanalysis. Obstetrics and Gynecology. 2016;128(4):713-723.
Thompson R, Dejong K, Lo J. Marijuana use in pregnancy: A review. Obstetrical
and Gynecological Survey. 2019;74(7):415-428.
Chabarria KC, Racusin DA, Antony KM, et al. Marijuana use and its effects in
pregnancy. American Journal of Obstetrics and Gynecology.
2016;215(4):506.e501-506.e507.
Goler N, Conway A, Young-Wolff KC. Data Are Needed on the Potential
Adverse Effects of Marijuana Use in Pregnancy. Annals of internal medicine.
2018;169(7):492-493.
Vieira K. Effects of Drug and Alcohol Use on Weight Change.
https://drugabuse.com/guides/substance-abuse-and-weight-change/. Accessed July
19, 2020.
ACOG Committee Opinion No. 650: Physical Activity and Exercise During
Pregnancy and the Postpartum Period. Obstet Gynecol. 2015;126(6):e135-142.
Calculate Your Body Mass Index National Heart, Lung, and Blood Institute
https://www.nhlbi.nih.gov/health/educational/lose_wt/BMI/bmicalc.htm.
Accessed December, 2019.
Weight, fertility, and pregnancy. U.S. Department of Health & Human Services
https://www.womenshealth.gov/healthy-weight/weight-fertility-and-pregnancy.
Updated December 27, 2018. Accessed March 31, 2020.
Being Overweight During Pregnancy March of Dimes.
https://www.marchofdimes.org/pregnancy/being-overweight-duringpregnancy.aspx#. Published 2020. Accessed March 31, 2020.
Lobo LL, Kumar HU, Mishra T, et al. Small-for-gestational-age versus
appropriate-for-gestational-age: Comparison of cord blood lipid profile & insulin
levels in term newborns (SAGA-ACT study). Indian J Med Res.
2016;144(2):194-199.
Weight Gain During Pregnancy The American College of Obstetricians and
Gynecologists. https://www.acog.org/Clinical-Guidance-andPublications/Committee-Opinions/Committee-on-Obstetric-Practice/WeightGain-During-Pregnancy?IsMobileSet=false. Published 2013. Accessed December
2019.
Dekker GA, Lee SY, North RA, McCowan LM, Simpson NAB, Roberts CT. Risk
factors for preterm birth in an international prospective cohort of nulliparous
women. PloS one. 2012;7(7).

40

49.
50.

51.

52.

53.
54.

55.

56.

57.

58.

59.

60.

61.

62.
63.

64.

Schempf AH, Strobino DM. Illicit drug use and adverse birth outcomes: Is it
drugs or context? Journal of Urban Health. 2008;85(6):858-873.
Berhanie E, Gebregziabher D, Berihu H, Gerezgiher A, Kidane G. Intimate
partner violence during pregnancy and adverse birth outcomes: a case-control
study. Reprod Health. 2019;16(1):22.
Ko JY, Tong VT, Bombard JM, Hayes DK, Davy J, Perham-Hester KA.
Marijuana use during and after pregnancy and association of prenatal use on birth
outcomes: A population-based study. Drug Alcohol Depend. 2018;187:72-78.
Garcia-Flores V, Romero R, Furcron AE, et al. Prenatal Maternal Stress Causes
Preterm Birth and Affects Neonatal Adaptive Immunity in Mice. Front Immunol.
2020;11:254.
DiPietro JA, Christensen AL, Costigan KA. The pregnancy experience scale-brief
version. J Psychosom Obstet Gynaecol. 2008;29(4):262-267.
Dotters-Katz SK, Smid MC, Manuck TA, Metz TD. Risk of neonatal and
childhood morbidity among preterm infants exposed to marijuana. Journal of
maternal-fetal & neonatal medicine. 2017;30(24):2933‐2939.
Mark K, Desai A, Terplan M. Marijuana use and pregnancy: prevalence,
associated characteristics, and birth outcomes. Arch Womens Ment Health.
2016;19(1):105-111.
Prenatal care and tests. U.S. Department of Health & Human Services.
https://www.womenshealth.gov/pregnancy/youre-pregnant-now-what/prenatalcare-and-tests. Updated January 30, 2019. Accessed April 1, 2020.
Kotelchuck M. An evaluation of the Kessner Adequacy of Prenatal Care Index
and a proposed Adequacy of Prenatal Care Utilization Index. Am J Public Health.
1994;84(9):1414-1420.
Special Supplemental Nutrition Program for Women, Infants, and Children
(WIC). U.S. Department of Agriculture. https://www.fns.usda.gov/wic. Published
2020. Accessed April 1, 2020.
Teen Pregnancy Issues and Challenges. American Pregnancy Association.
https://americanpregnancy.org/unplanned-pregnancy/teen-pregnancy-issueschallenges/. Published 2020. Accessed April 1, 2020.
Pregnancy After Age 35. March of Dimes.
https://www.marchofdimes.org/complications/pregnancy-after-age-35.aspx#.
Updated April 2016. Accessed April 1, 2020.
Preterm Birth. Centers for Disease Control and Prevention.
https://www.cdc.gov/reproductivehealth/maternalinfanthealth/pretermbirth.htm.
Updated October 21, 2019. Accessed April 1, 2020.
Yang J, Baer RJ, Berghella V, et al. Recurrence of Preterm Birth and Early Term
Birth. Obstet Gynecol. 2016;128(2):364-372.
Sclowitz IK, Santos IS, Domingues MR, Matijasevich A, Barros AJ. Prognostic
factors for low birthweight repetition in successive pregnancies: a cohort study.
BMC Pregnancy Childbirth. 2013;13:20.
Chang JC, Tarr JA, Holland CL, et al. Beliefs and attitudes regarding prenatal
marijuana use: Perspectives of pregnant women who report use. Drug and
Alcohol Dependence. 2019;196:14-20.

41

65.

66.

67.

68.

69.
70.

71.
72.

73.

74.

75.

76.
77.

78.

Price HR, Collier AC, Wright TE. Screening Pregnant Women and Their
Neonates for Illicit Drug Use: Consideration of the Integrated Technical, Medical,
Ethical, Legal, and Social Issues. Front Pharmacol. 2018;9:961.
Dugosh KC, J. Clinical assessment of substance use disorders. UpToDate.
https://www.uptodate.com/contents/clinical-assessment-of-substance-usedisorders?search=clinical%20assessment%20of%20substance%20use%20disorde
rs&source=search_result&selectedTitle=1~150&usage_type=default&display_ra
nk=1. Updated February 25, 2019. Accessed March 7, 2020.
Rodriguez CE, Sheeder J, Allshouse AA, et al. Marijuana use in young mothers
and adverse pregnancy outcomes: a retrospective cohort study. Bjog.
2019;126(12):1491-1497.
Metz TD, Allshouse AA, Hogue CJ, et al. Maternal marijuana use, adverse
pregnancy outcomes, and neonatal morbidity. American Journal of Obstetrics and
Gynecology. 2017;217(4):478.e471-478.e478.
Fried PA, Watkinson B, Willan A. Marijuana use during pregnancy and decreased
length of gestation. Am J Obstet Gynecol. 1984;150(1):23-27.
Linn S, Schoenbaum SC, Monson RR, Rosner R, Stubblefield PC, Ryan KJ. The
association of marijuana use with outcome of pregnancy. Am J Public Health.
1983;73(10):1161-1164.
Hatch EE, Bracken MB. Effect of marijuana use in pregnancy on fetal growth.
American Journal of Epidemiology. 1986;124(6):986-993.
Gray TR. Identifying prenatal cannabis exposure and effects of concurrent
tobacco exposure on neonatal growth. Clinical chemistry (Baltimore, Md).
2010;56(9):1442-1450.
Ways Marijuana is Used: A Guide for Parents. Partnership.
https://drugfree.org/parent-blog/ways-marijuana-used-parents-guide/. Published
2015. Updated April 29, 2015. Accessed March 24, 2020.
Janisse JJ, Bailey BA, Ager J, Sokol RJ. Alcohol, tobacco, cocaine, and marijuana
use: Relative contributions to preterm delivery and fetal growth restriction.
Substance Abuse. 2014;35(1):60-67.
Prenatal progestogens for preventing preterm birth in women with a multiple
pregnancy. Cochrane Library.
https://www.cochrane.org/CD012024/PREG_prenatal-progestogens-preventingpreterm-birth-women-multiple-pregnancy. Accessed April 2, 2020.
Bailey BA, Wood DL, Shah D. Impact of pregnancy marijuana use on birth
outcomes: results from two matched population-based cohorts. J Perinatol. 2020.
El Marroun H, Tiemeier H, Steegers EA, et al. Intrauterine cannabis exposure
affects fetal growth trajectories: the Generation R Study. J Am Acad Child
Adolesc Psychiatry. 2009;48(12):1173-1181.
Gorelick D. Cannabis use and disorder in adults: Pathogenesis, pharmacology,
and routes of administration. UpToDate.
https://www.uptodate.com/contents/cannabis-use-and-disorder-in-adultspathogenesis-pharmacology-and-routes-ofadministration?search=marijuana%20potency&source=search_result&selectedTit
le=2~150&usage_type=default&display_rank=2. Published 2019. Updated
December 13, 2019. Accessed March 24, 2020.

42

79.

Baer RJ, Chambers CD, Ryckman KK, Oltman SP, Rand L, Jelliffe-Pawlowski
LL. Risk of preterm and early term birth by maternal drug use. J Perinatol.
2019;39(2):286-294.

43

CHAPTER 3: METHODS
3.1 Study Design
We propose a prospective cohort study analyzing the effect of prenatal marijuana
exposure on select neonatal outcomes, compared to matched subjects without marijuana
exposure in utero. Pregnant women will be age-matched. Researchers collecting neonatal
outcomes at birth will be blinded to exposure status.

3.2 Study Population and Sampling
The source population will be pregnant women in Boston, Massachusetts where
recreational marijuana was legalized in 2016. Women will be identified using
consecutive convenience sampling. All pregnant women presenting for their first prenatal
care visit in a private or public obstetric practice, midwifery practice, or hospital clinic in
Boston that plans to deliver at Brigham and Women’s Hospital or Massachusetts General
Hospital will be asked to participate.
Women will be asked to participate if they have a singleton pregnancy with an
expected due date in our study period. They must also agree to regular urine drug screens
and reporting daily marijuana use. Exclusion criteria will be polysubstance use (tobacco,
alcohol, illicit drugs, opioids, methadone, amphetamines, benzodiazepines, and
barbiturates), multiple-birth pregnancy, maternal age <18, a known congenital or
chromosomal fetal anomaly, stillbirth or underlying medical condition (chronic
hypertension or heart disease requiring medication, diabetes, renal disease, systemic
lupus erythematosus, antiphospholipid syndrome, sickle cell disease, human
immunodeficiency virus (HIV), previous cervical knife cone biopsy, 3 or more pregnancy
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terminations, and 3 or more miscarriages). Women with any other medical condition
requiring medicinal marijuana will also be excluded. This will reduce the inclusion of
women with medical conditions that may increase the risk of adverse neonatal outcomes.
After meeting the study criteria, exposure group participants will be age-matched to nonexposure group participants.

3.3 Recruitment
We will recruit women at their first prenatal care visit. Patients will be screened
by their healthcare providers to determine eligibility based on inclusion and exclusion
criteria. If women agree to participate, they will be contacted by a researcher to describe
study expectations and to obtain written consent. After receiving consent, we will search
patients’ medical records to confirm eligibility. Eligible participants will then be given
the first urine drug screen and complete the first participant survey. After identifying the
sample of women with marijuana use, a researcher will provide instructions on how to
report daily marijuana consumption. As an incentive, a $25 visa gift card will be given to
every participant at the completion of the study.

3.4 Subject Protection and Confidentiality
Massachusetts General Hospital and Brigham and Women’s Hospital are a part of
the Partners Healthcare network. The institutional review board of Partners Healthcare is
the Partners Human Research Committee. For our study, we will seek an ethical review
by the Partners Human Research Committee and the Human Investigation Committee of
Yale University School of Medicine. If approved, written informed consent (Appendix
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D) will then be obtained from all women before study data is gathered. Each participant
will be assigned an identification code that will be used on all data collection forms and
in the statistical analysis.

3.5 Study Variables and Measures
3.5.1 Independent Variable
The independent variable is marijuana exposure in utero. This will be
operationalized as maternal marijuana use once or more during pregnancy. Daily
marijuana use will be self-reported, and participants will have a urine drug screen at each
prenatal care visit. Any other drug use from the exclusion criteria list will warrant
removal from the study.

3.5.2 Dependent Variable
The primary dependent variable is low birth weight. This is a dichotomous
outcome. Neonates less than 2,500 grams at birth will be classified as LBW, while
neonates greater than 2,500 grams at birth will not be classified as LBW.
There are four secondary outcomes of interest. The first is spontaneous preterm
birth which is a dichotomous variable. Neonates born before 37 weeks’ gestation will be
classified as preterm, while neonates born after 37 weeks’ gestation will be classified as
full term. The second outcome is small for gestational age which is also a dichotomous
variable. Neonates less than the 10th percentile will be classified as SGA. Neonates above
the 10th percentile will not be classified as SGA. Our last dichotomous secondary
outcome will be NICU admission. This will include neonates that require intensive care
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during the hospital admission immediately following birth. Our final secondary outcome
is Apgar scores. This is an ordinal variable measured from 0-10.

3.5.3 Potential Confounding
Neonatal outcomes at birth can be affected by many factors during pregnancy.
Potential confounding factors we will control for are maternal age, race, ethnicity, marital
status, parity, pregnancy intention, prenatal care, prior preterm birth, prior LBW neonate,
pre-pregnancy BMI, gestational weight gain, exercise, maternal education, Medicaid
and/or WIC recipient, income level, intimate partner violence, and overall stress. In our
cohort, the exposure and non-exposure groups will be age-matched. All confounding
variables will be assessed in a participant survey (Appendix A).
Pregnancy intention will be categorized based on response to the question “How
did you feel when you first found out you were pregnant?” Answer choices are adapted
from prior studies.1,2 Women that respond with “I wanted to be pregnant at a later time,”
“I don’t want to be pregnant now or at any time in the future,” and “I’m not sure what I
wanted,” will be classified as an unintended pregnancy. If women select the fourth
answer choice of “I wanted to be pregnant now,” then they will be categorized as an
intended pregnancy. Multiparous women that cannot recall gestational age or birth weight
from a prior delivery can select “I am not sure” on the survey. Researchers will gather
this data from medical records for all participants to ensure accuracy. Prenatal care
adequacy will be determined through the Kotelchuck Index (Appendix C), assessed after
the last prenatal care visit. Exercise is described as 30 minutes of moderate-intensity
aerobic activity. To be adequate, it should be done on 5 or more days each week. Intimate
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partner violence screening has been adapted from a prior report.3 If women report being
pushed, tripped, hit, slapped, kicked, choked, or physically hurt in any other way during
pregnancy, they will be categorized as having experienced intimate partner violence.
Overall stress will be measured using the brief version of the Pregnancy Experience Scale
(Appendix A). The brief version has a 4-point Likert scale for ten of the most commonly
reported uplifts and ten of the most commonly reported hassles during pregnancy.4 This
scale is included in the participant survey.
Characteristic
Maternal
Race

Variable

Description

Categorical

Ethnicity
Marital Status
Parity
Pregnancy Intention
Prenatal Care

Categorical
Categorical
Ordinal
Dichotomous
Ordinal

Prior Preterm Birth
Prior LBW Neonate
Pre-pregnancy BMI
Gestational Weight Gain

Dichotomous
Dichotomous
Ordinal
Ordinal

Exercise

Dichotomous

Education

Ordinal

Medicaid Recipient
WIC Recipient
Income Level

Dichotomous
Dichotomous
Ordinal

Intimate Partner Violence

Dichotomous

Stress Level

Ordinal

American Indian or Alaska Native, Asian,
Black or African American, Native Hawaiian
or Other Pacific Islander, White
Hispanic or Latino, Not Hispanic or Latino
Single, Married, Separated, Divorced, Widow
0, 1, 2, 3 or more
Intended, Unintended
Inadequate, Intermediate, Adequate,
Adequate Plus
Prior PTB, No Prior PTB
Prior LBW Neonate, No Prior LBW Neonate
Underweight, Normal, Overweight, Obese
Below, Within or Above IOM
Recommendations
Adequate: ≥5 days/week
Inadequate: <5 days/week
Completed: < high school, High School or
GED, Higher Education/College
Primary insurance (yes/no)
Recipient (yes/no)
<185% FPL, 185-250% FPL, 250-400% FPL,
>400% FPL
Experienced Violence,
Did Not Experience Violence
PES Brief - Likert Scale

Table 1. Descriptive Characteristics of Study Population
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3.6 Additional Methodology Considerations
Marijuana use history will be determined by maternal self-report and urine drug
screens. This information will be obtained and updated at every prenatal care visit. We
will use urine drug screens because they are less expensive and non-invasive compared to
maternal serum assays. If women report marijuana use or have a positive urine drug
screen, they will be asked to report their daily consumption. Reporting this information
daily will reduce bias from asking participants to recall use during each prenatal care
visit. It is difficult to accurately report prior behavior that can change over time (i.e. may
vary from week to week). Although self-reporting is not an objective measure of use, it is
the only method to obtain frequency and quantity of consumption. Conducting the study
in Boston, Massachusetts where recreational marijuana is legal, may reduce social
desirability bias that could occur in an area without legalization.
Participants will receive daily text messages to report marijuana use. Standard text
messages will ask the method and amount of consumption. First, a text message will ask
“Did you use marijuana today?” If the reply is “No” then no further message will be sent.
If the reply is “Yes” then a message saying, “What method did you use and how much
did you consume?” will be sent. Methods will include smoking, vaping, and oral
consumption. Participants can report the number of bowls, blunts, joints, or grams of
marijuana that was smoked. From these reports, all consumption will be converted to
grams. To start, a bowl will convert to 3 joints, and a blunt will convert to 4.5 The total
number of joints will then be converted to grams. On average, one joint contains 0.66
grams of marijuana.6 This will be the conversion for participants that do not directly
report their use in grams. For participants that vape, the number of oil cartridges used and
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the number of grams from each cartridge will be recorded. Lastly, oral consumption will
be reported in grams. If edibles are made by the participant, they will be asked to measure
the marijuana content in the recipe. If edibles are purchased, they can gather this
information from the seller or product packaging. Since Massachusetts has marijuana
dispensaries, weight in grams can more easily be identified. Participants that purchase
marijuana with packaging will be asked to include packaging data. The text message data
software will be selected at the beginning of this study based on the resources available.
Additionally, marijuana use journals (Appendix B) will be provided to participants that
wish to keep a written history of use. These journals will also guide participants on how
to most accurately report quantity of use and will be explained in detail by the research
assistants at the beginning of the study.
At the end of pregnancy participants will be stratified by total consumption,
frequency of use and timing of exposure. For total consumption, each participant will be
stratified by total grams consumed. For frequency of use, women will be stratified into
four categories. The four categories will be of no use, light use, moderate use, and heavy
use. Light use will be once per month or less. Moderate use will be 2-4 times per month
and heavy use will be 4 times per month or more. Total consumption and frequency will
be used to analyze a potential dose-dependent relationship. Lastly, women will be
stratified by timing of exposure. This analysis will measure a potential association
between trimester of use and adverse neonatal outcomes.
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3.7 Data Collection
For our study, we will use a survey to collect information on maternal age, race,
ethnicity, marital status, parity, pregnancy intention, prenatal care, prior preterm birth,
prior LBW neonate, pre-pregnancy BMI, gestational weight gain, exercise, education,
Medicaid, WIC, income, intimate partner violence and overall stress (Appendix A). This
information will be used to analyze descriptive and confounding factors. The first survey
will be given by a researcher to guide patients and answer any questions that arise.
Subsequent surveys will be given by research assistants. The same survey will be given at
each prenatal care visit to update any changes since the patient was last seen. If a research
assistant cannot attend a prenatal care visit, the survey can be administered over the
phone.
Drug use information will be collected at each prenatal care visit as well. The
participant survey will include a substance use history where the mother can self-report
drug use. Urine drug screens at each visit will objectively test for THC, amphetamines,
cocaine, opiates, PCP, barbiturates, benzodiazepines and methadone. Urine samples will
also be tested for recent tobacco and alcohol consumption. The information collected for
this study will be confidential and not disclosed to providers. However, providers can
screen patients at their own discretion and patients can disclose their marijuana use
history directly.
After birth, information on neonatal outcomes will be collected from medical
records. Birth weight, gestational age, Apgar scores, and NICU admission can be easily
obtained from neonatal medical charts. Birth weight and gestational age can be used to
calculate if a neonate is SGA, if this information is not already documented in the
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medical record. Brigham and Women’s Hospital and Massachusetts General Hospital
both use Epic electronic medical records which will provide easy remote access for
researchers obtaining birth outcomes. The research assistants assigned to neonatal record
retrieval will be blinded to exposure status.

3.8 Sample Size Calculation
Our study is designed to measure the association between prenatal marijuana
exposure and adverse neonatal outcomes at birth. Our primary outcome is low birth
weight. One of the most recent reports analyzing this association found a low birth
weight among 11.5% of non-users and 20.9% of marijuana users.7 Using this effect size
of 9.4%, a significance level of 0.05 (α), and 80% power, we calculated a minimum
sample size of 480 participants. This yields a sample of 240 women in the exposure
group and 240 women in the non-exposure group (Appendix E). This calculation is
derived from the algorithm by Power and Precision version 4.0 software (BioStat Inc.).
We will sample beyond the minimum sample size in anticipation of drop out and
women meeting exclusion criteria at some point after their initial presentation. Prior
studies have experienced up to 15% loss of participants in their total sample population.5,8
To account for 15% loss during the study period we will obtain a sample size of 552
women. There will be 276 women in the exposure group and 276 women in the nonexposure group.
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3.9 Statistical Analysis
First, exposure and non-exposure group participants will be age-matched. Then,
confounding factors described as ordinal variables will be analyzed using paired t-tests,
while confounding factors described as categorical or dichotomous variables will be
analyzed using Chi-squared tests. Confounding variables that will be tested can be found
in Table 1. We will examine the association of each confounder with the exposure and
outcome. Confounders that meet a significance threshold of p<0.1 will be included in our
models. Confounders will also be analyzed to determine if two variables are highly
correlated (r>0.7). If two variables have high correlation, the variable that has a stronger
association with the outcome of this study will be included in the models. Next, we will
test our unadjusted hypothesis using Chi-squared test for matched subjects with a
dichotomous outcome (low birth weight). Then, to test our adjusted hypothesis to control
for confounding factors we will use a conditional logistic regression. Lastly, we will
analyze secondary outcomes. For spontaneous preterm birth, SGA, and NICU admission,
all dichotomous outcomes, we will use Chi-squared tests. For Apgar scores, an ordinal
outcome, we will use paired t-test. To test secondary outcomes while controlling for
confounding factors, we will use logistic regression for dichotomous secondary outcomes
and linear regression for ordinal secondary outcomes. All analyses will be conducted
using SPSS software (SPSS, Chicago, IL).

3.10 Timeline and Resources
Our study will be conducted in two years. The first month will be used to identify
Boston prenatal care practices that are willing to participate in the study. The next 14

53

months will then be used for patient recruitment. Participants will not be recruited in the
last nine months of the study period because selection during this time risks women
delivering after the two-year time limit. These last nine months will be used to follow and
gather information from women previously selected for the study.
Personnel will include a principal investigator to supervise all phases of the study.
Under the principal investigator will be two research assistants. Each assistant will be
assigned to one of the two Boston hospitals. They will be responsible for the women that
plan to deliver at their assigned hospital. Thus, after a patient is identified by their
healthcare provider, the research assistant assigned to their intended hospital will
administer the participant surveys. Two additional assistants will be used to obtain
neonatal outcomes after delivery. There will be one assistant assigned to each hospital
that will be blinded to the exposure status of the mother. Personnel will also include one
physician associate student to assist with data organization, statistical analysis, and
writing the final report.
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CHAPTER 4: CONCLUSION
4.1 Advantages
As an increasing number of women are reporting marijuana use during pregnancy,
it is imperative to determine the potential risk this exposure has on neonatal outcomes.
The key advantages of our study are how we address past limitations in research. First,
our study has a prospective design. This will inherently reduce the limitations of a
retrospective design. We can create strict exclusion criteria to identify a specific sample
of pregnant women. Most importantly, our criteria will exclude women with
polysubstance use. Excluding women with other substance use during pregnancy will
reduce major confounding factors. This has rarely been achieved in previous research.
Additionally, a prospective design will reduce recall bias in self-reported drug use.
Participants will have the resources to report daily marijuana use so it does not have to be
recalled at each prenatal care visit. Finally, this design will measure marijuana at its
current potency. Prior studies have analyzed marijuana of lower potency which may not
have had the same adverse effect.
A second advantage will be our method to determine exposure status. Marijuana
use will be identified with maternal self-report and urine drug screens. We will use urine
drug screens as an objective measure to reduce the misclassification that could occur
from using subjective self-report alone. Additionally, conducting our study in Boston
may reduce social desirability bias. Recreational marijuana legalization may reduce the
number of women falsely reporting exposure from fear of social or legal consequences.
This is more likely to occur where recreational marijuana has not been legalized.
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Lastly, our data collection design is an advantage. Many prior studies were unable
to collect information on frequency, quantity or timing of marijuana use. We will analyze
a potential dose-dependent relationship as well as a potential association between
trimester of use and adverse neonatal outcomes. Our data collection of neonatal outcomes
will also be enhanced by blinding the researcher to exposure status. This will strengthen
the internal validity of our study.

4.2 Disadvantages
Although our study addresses several limitations in previous research, certain
limitations remain. First, our study design must be a prospective cohort study rather than
a randomized control trial. We cannot ethically assign women to an exposure that may
cause harm. In consequence, we cannot standardize the marijuana consumed among
participants in the exposure group. In addition to quantity, the potency of marijuana may
vary among participants and for the same participant over time when using different
products. Measuring the THC content of the marijuana used by each participant would
provide a more accurate measure of use, but this is not feasible.
Second, there are limitations when using self-report. Currently, there is no
uniform method to collect data on marijuana use. Although standardized and validated
methods exist for self-reported alcohol and tobacco use,1 these methods are not
transferable to marijuana. While alcohol and cigarettes have standardized potency and
quantity in commercially available products, marijuana does not. Marijuana products
purchased from legal dispensaries have these qualities, but when purchased from nonregulated sellers it does not. This prevents an accurate measure of marijuana in self-made
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joints, blunts, or bowls. Until a standardized and validated method is developed for
marijuana, this will be a limitation in research measuring the quantity of consumption.
Additionally, there are limitations in our sampling method. We will use
consecutive convenience sampling at two major hospitals in Boston. A non-random
sampling method may introduce selection bias and weaken external validity. Another
potential bias in our data collection may arise from maternal self-report. Although
marijuana has been legalized in Massachusetts for recreational use, use during pregnancy
may have a social stigma. This stigma and the fear of consequences may lead to
underreporting use. Furthermore, sampling from an urban population may reduce the
generalizability of results. Although we will control for many significant confounding
factors, it is impossible to control for every potential covariate. There may be residual
confounding in our study population.
Daily reporting of marijuana use may lead to participant fatigue. We will reduce
participant fatigue by using a text message service to obtain patterns of daily use. These
text messages will prompt participants for data collection. This will reduce fatigue from
having participants maintain their own daily record to provide at each prenatal care visit.
Using text messages to collect data will restrict the sample population to women with
mobile devices, but we do not expect this to considerably limit our sample. It may
slightly reduce the generalizability of our results.
Lastly, daily reporting of marijuana use may cause participants to become more
cognizant of their consumption. This may cause some women to change or reduce their
previous patterns of use. Unfortunately, this is an unavoidable limitation as recording
daily consumption is a key advantage in this study to determine a potential dose-
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dependent relationship. We will maintain a non-judgmental environment to reduce
influencing women’s individual decisions throughout pregnancy.

4.3 Clinical Significance
Current research on the association between prenatal marijuana exposure and adverse
neonatal outcomes is inconsistent and limited. We assume marijuana exposure in utero
negatively impacts neonatal development and can be measured through various outcomes
at birth. However, given the uncertainty of currently available research, the true risk
remains unknown. A recent report from 2017 found that 10% of women would increase
marijuana use during pregnancy if it became legal in their state.2 With expanding
legalization and increasing use, it is imperative to study potential consequences now
before a larger population of neonates are potentially put at risk.
Initially, our study will bring awareness to these changing patterns of use. Greater
awareness among providers can enhance drug screening during patient visits to develop a
more thorough patient history. This is not only important for providers working with
pregnant populations, but any healthcare field working with women in their reproductive
years. Marijuana use among women is most frequently reported during childbearing age.3
Various fields can ultimately provide early education on drug use before women become
pregnant and present to prenatal care practices. Early intervention is crucial in preventing
teratogenic exposures in early pregnancy.
After increasing awareness and emphasizing the magnitude of the population at risk,
results from our study can improve evidence-based practice recommendations. The
current ACOG recommendation is to discourage all marijuana use until more evidence
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becomes available.4 Presently, providers feel uncomfortable making recommendations to
their patients in the absence of clear evidence.5 If our study can determine the association
with greater certainty, providers may feel more comfortable educating patients on
potential risks. This can enhance patient-provider communication.
Lastly, if our study shows an increased risk of adverse neonatal outcomes, our results
can support future efforts to reduce marijuana use during pregnancy. Education on
marijuana use is limited with the conflicting information available. A more reliable study
could encourage prenatal care practices and outreach programs to provide more robust
information to women. Interventions to reduce adverse neonatal outcomes can ultimately
lessen healthcare costs and the resources needed to care for unwell neonates. Reducing
adverse outcomes early in life can also reduce associated medical complications later in
life. Conducting our study now will support an early intervention to an increasing public
health concern. As marijuana use rises, it is crucial to identify the risk during pregnancy
to protect safe and healthy neonatal development.
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APPENDIX A: Participant Survey
Participant Survey
Participant Identification Code:
Today’s Date:
Age _____
Race
a)
b)
c)
d)
e)

American Indian or Alaska Native
Asian
Black or African American
Native Hawaiian or Other Pacific Islander
White

Ethnicity
a) Hispanic or Latino
b) Not Hispanic or Latino
What is your current marital status?
a) Single
b) Married
c) Separated
d) Divorced
e) Widow
How many prior live births have you had? (For pregnancies beyond 24 weeks’
gestation)
a) 0
b) 1
c) 2
d) 3 or more
How did you feel when you first found out you were pregnant?
a) I wanted to be pregnant now
b) I wanted to be pregnant at a later time
c) I didn’t want to be pregnant now or at any time in the future
d) I’m not sure what I wanted
How far along is your pregnancy? ______ weeks’ gestation
How far along were you when you had your first prenatal care visit? ______ weeks’
gestation
How many prenatal care visits have you had thus far? ______
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Have you had a prior pregnancy with a preterm birth? (Before 37 weeks’ gestation)
a) Yes
b) No
c) I am not sure
Have you had a prior pregnancy with an infant that was born with a low birth
weight? (<2,500 grams)
a) Yes
b) No
c) I am not sure
What was your body weight right before you became pregnant? ______ pounds
What is your height? _____ feet _____ inches
How much weight have you gained during pregnancy thus far? ______ pounds
How many days a week do you engage in 30 minutes of moderate-intensity aerobic
exercise?
a) 5 or more days a week
b) Less than 5 days a week
What is the highest level of education you completed? (Received a diploma)
a) Did not complete high school
b) High School or GED
c) Higher Education/College
Is Medicaid your primary source of insurance during pregnancy?
a) Yes
b) No
Do you qualify/have you received support from WIC during your pregnancy?
a) Yes
b) No
What is the current annual income for your household? ______
What is the size of your household? (Including yourself) ______
During your current pregnancy, have you been pushed, tripped, hit, slapped,
kicked, choked, or physically hurt in any other way by your partner?
a) Yes
b) No
Please complete the Pregnancy Experience Scale below.
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This scale has 10 items you may find uplifting and 10 items you may find upsetting
during pregnancy. Please circle the number that corresponds to how you are feeling right
now.
Pregnancy Experience Scale- Brief

DiPietro et al.
Substance Use History
Since your pregnancy began, have you used marijuana?
a) Yes
b) No
Since your pregnancy began, have you consumed alcohol?
c) Yes
d) No
Since your pregnancy began, have you used tobacco or nicotine products?
a) Yes
b) No
Since your pregnancy began, have you used amphetamines (meth, speed, ecstasy),
cocaine (coke, crack), opiates (heroin, opium, codeine, morphine), phencyclidine (PCP,
angel dust), barbiturates (phenobarbital, butalbital, secobarbital, downers),
benzodiazepines (valium, Librium, Xanax) or methadone?
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a) Yes
b) No
If you used a substance during pregnancy not listed in the previous question, please
indicate it here ______________________.
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APPENDIX B: Marijuana Use Journal
Marijuana Use Journal (Example Page)

Friday January 1, 2021
Marijuana
Use?
Yes
No

Identification code: 01234
Smoking

Grams:
Joints: 1
Bowls:
Blunts:

Vapor
% Cartridge Used:

Oral
Grams:

Total Cartridge Amount:

Saturday January 2, 2021
Marijuana
Use?
Yes
No

Smoking
Grams:
Joints:
Bowls:
Blunts:

Vapor
% Cartridge Used: 25%

Oral
Grams:

Total Cartridge Amount: 1 gram

Sunday January 3, 2021
Marijuana
Use?
Yes
No

Smoking
Grams:
Joints:
Bowls:
Blunts:

Vapor
% Cartridge Used:

Oral
Grams: 0.5

Total Cartridge Amount:

Monday January 4, 2021
Marijuana
Use?
Yes
No

Smoking
Grams:
Joints:
Bowls:
Blunts:

Vapor
% Cartridge Used:

Oral
Grams:

Total Cartridge Amount:

In the Marijuana Use box please circle Yes or No for each day.
Please circle the method used on the given day. Please provide a number for the marijuana amount
consumed. Only record the amount in the column below the method. For cartridges, please provide
the percent of the cartridge that was used and the total amount in the cartridge when it was full.
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APPENDIX C: Kotelchuck Index
Adequacy of Prenatal Care Utilization Index

- Kotelchuck. 1994.
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APPENDIX D: Participant Consent Form
WRITTEN CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT

Study Title: Prenatal Marijuana Use and Potential Adverse Neonatal Outcomes
Principal Investigator: Tracy Buechele
Affiliation: Yale University School of Medicine, Massachusetts General Hospital &
Brigham and Women’s Hospital

Invitation to Participant and Description of Project
We are inviting you and your baby to participate in a research study designed to look at
neonatal outcomes at birth. You have been selected because you are 18 years of age or
older and you have a singleton, uncomplicated pregnancy. Approximately 552 women
will participate in this study. Half of this sample will be women reporting no drug use
during pregnancy while the other half will be women using marijuana during pregnancy.
Neonatal outcomes at birth will be compared between the two groups to see if there are
differences.
In order to decide whether or not you wish to be a part of this research study you should
know enough about its risks and benefits to make an informed decision. This permission
form gives you detailed information about the study, which a member of the research
team will discuss with you. This discussion should go over all aspects of this research: its
purpose, the procedures that will be performed and any risks of the procedures. Once you
understand the study, you will be asked if you wish to participate; if so, you will be asked
to sign this form.

Description of Procedures
If you agree to participating in this observation study, you will be followed by the
research team throughout your pregnancy to delivery.
▪

▪

Initial participant selection occurs by healthcare providers. You were selected by
your provider because you meet study criteria and plan to give birth at
Massachusetts General Hospital or Brigham and Women’s Hospital. If you agree
to participate, we will confirm your eligibility by reviewing your medical record.
After signing the consent form, you will be contacted by a researcher to fill out a
participant survey. This will ask you a number of questions on maternal history,
social history, demographic information, and substance use history since
becoming pregnant. This survey will be completed at every prenatal care visit.
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▪

▪

▪

▪
▪

The purpose of this survey is to gather information that may impact neonatal
outcomes at birth.
At each prenatal care visit you will be given a urine drug screen. This will test for
marijuana, alcohol, nicotine, amphetamines, cocaine, opiates, phencyclidine
(PCP), barbiturates, benzodiazepines and methadone. Use of any substance
besides marijuana during your pregnancy will remove you from this study.
For the sample of women that use marijuana during pregnancy, you will be asked
to report daily use through our text message service. These messages will record
frequency and quantity of marijuana use. The purpose of this record is to have
accurate information on marijuana consumption during pregnancy.
After your baby’s birth, neonatal records will be obtained from the electronic
medical record. We will gather your baby’s birth weight, gestational age, Apgar
scores and if there was intensive care required after birth. These outcomes will be
compared between non-marijuana exposed and marijuana exposed neonates.
Your participation in this study will end after neonatal records are obtained.
All medical decisions will be made by your healthcare provider. Researchers will
have a non-judgmental observational role only.

You will be told of any significant new findings that are developed during the course of
your participation in this study that may affect your willingness to continue to participate.
Research results will not be returned to your doctor. If research results are published,
your name and other personal information will not be given.

Risks and Inconveniences
There are no physical risks associated with this study. Urine drug screens are noninvasive and will be performed by trained medical professionals.
Recording daily marijuana use may come as an inconvenience to you. Research assistants
will be available for questions at any time and encourage your full participation.
You may be uncomfortable revealing personal information in participant surveys. Every
effort will be made to keep your information confidential. A breach of confidentiality is
unlikely to occur, as all study investigators are trained in research privacy.

Benefits
This study aims to determine if there are differences in neonatal outcomes at birth from in
utero marijuana exposure verses no exposure. Although there may be no direct benefit for
you from your participation, this research will advance our understanding of how
marijuana use may impact pregnancy.
Economic Considerations
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Participant surveys will be provided free of charge. Urine drug screens should be covered
by your health insurance, but if not, our study will cover the cost. The text message fees
should be covered by your cellular service. There are no other costs associated with this
study so you should experience no financial burden. In addition, completion of this study
will provide a $25 visa gift card to use at a location of your choice.

Confidentiality and Privacy
Any identifiable information that is obtained in connection with this study will remain
confidential and will be disclosed only with your permission or as required by U.S. or
State Law. Examples of information that we are legally required to disclose include abuse
of a child, which we must report to the Department of Children and Families. Information
will be kept confidential by using only identification numbers on study forms, storing
signed forms in locked cabinets and password protecting data stored on a computer.
When the results of the research are published or discussed in conferences, no
information will be included that would reveal your identity unless your specific
permission for this activity is obtained.
We understand that information about your health is personal, and we are committed to
protecting the privacy of that information. If you decide to be in this study, the researcher
will get information that identifies your personal health information. This may include
information that might directly identify you, such as name and address, telephone
number, and email address, or mobile phone number. This information will be deidentified at the earliest reasonable time after we receive it, meaning we will replace your
identifying information with a code that does not directly identify you. The principal
investigator will keep a link that identifies you and your coded information, and this link
will be kept secure and available only to the principal investigator or selected members of
the research team. Any information that can identify you will remain confidential. The
research team will only give coded information to others to carry out this research study.
The link to your personal information will be kept for 5 years, after which time the link
will be destroyed and the data will be anonymous. The data will be kept in this
anonymous form indefinitely.
The information about your health that will be collected in this study includes:
• Research study records
• Records about phone calls made as part of this study
• Records about your study visits
Information about your health may be used by or given to:
• The U.S. Department of Health and Human Services (DHHS) agencies
• Representatives from Yale University, the Yale Human Research Protection
Program and the Yale Human Investigation Committee (the committee that
reviews, approves and monitors research on human subjects), who are responsible
for ensuring research compliance. These individuals are required to keep all
information confidential.
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•

•
•
•
•

Representatives from the Partners Human Research Committee (the institutional
review board of Partners HealthCare for Massachusetts General Hospital &
Brigham and Women’s Hospital that must approve all human-subject research).
These individuals are required to keep all information confidential.
Individuals at Yale who are responsible for the financial oversight of research
including billings and payments
The Principal Investigator
Co-Investigators
Members of the Research Team

By signing this form, you authorize the use and/or disclosure of the information described
above for this research study. The purpose for the uses and disclosures you are
authorizing is to ensure that the information relating to this research is available to all
parties who may need it for research purposes.
All healthcare providers subject to HIPAA (Health Insurance Portability and
Accountability Act) are required to protect the privacy of your information. The research
staff at the Yale School of Medicine are required to comply with HIPAA and to ensure
the confidentiality of information.
If you choose to participate in this study, the investigators will check your electronic
medical record through EPIC to make sure you qualify. Any access to your electronic
medical record will be done consistent with HIPAA regulations.
Some of the individuals or agencies listed above may not be subject to HIPAA and
therefore may not be required to provide the same type of confidentiality protection. They
could use or disclose your information in ways not mentioned in this form. However, to
better protect your health information, agreements are in place with these individuals
and/or companies that require that they keep your information confidential.
You have the right to review and copy your health information in your medical record in
accordance with institutional medical record policies. This authorization to use and
disclose your health information collected during your participation in this study will
never expire.

Voluntary Participation and Withdrawal
You are free to choose not to participate in this study. Your health care outside the study,
the payment for your health care, and your health care benefits will not be affected if you
do not agree to participate. However, you will not be able to enroll in this research study
and will not receive study procedures as a study participant if you do not allow use of
your information as part of this study. You do not give up any of your legal rights by
signing this form.
Withdrawing from the Study
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If you do not become a subject, you are free to stop and withdraw from this study at any
time during its course.
To withdraw from the study, you can call a member of the research team at any time and
tell them you no longer want to take part. This will cancel any future appointments.
The researchers may withdraw you from participating in the research if necessary.
If you choose not to participate or if you withdraw it will not harm your relationship with
your own providers, Yale School of Medicine, Massachusetts General Hospital or
Brigham and Women’s Hospital.

Withdrawing Your Authorization to Use and Disclose Your Health Information
You may withdraw or take away permission to use and disclose your health information
at any time. You do this by calling or sending written notice to the Principal Investigator.
When you withdraw your permission, no new health information identifying you will be
gathered after that date. Information that has already been gathered may still be used and
given to others until the end of the research study, as necessary to ensure the integrity of
the study and/or study oversight.
You do not give up any of your legal rights by signing this form.
Questions
We have used technical terms in this form. Please feel free to ask about anything you
don’t understand and to consider this research and the permission form carefully – as
long as you feel is necessary – before you make a decision.

Authorization
I have read (or someone has read to me) this form and have decided to participate in the
project described above. Its general purposes, the particulars of my involvement and
possible hazards and inconveniences have been explained to my satisfaction. My
signature also indicates that I have received a copy of this consent form.
Name of Subject: ____________________
Signature: __________________________
Date: ______________________________
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___________________________
Signature of Principal Investigator

__________________
Date

or
___________________________
Signature of Person Obtaining Consent

__________________
Date

If you have any further questions about this project or if you have a research-related
problem, you may contact the Principal Investigator, Tracy Buechele.
If, after you have signed this form you have any questions about your privacy rights,
please contact the Yale Privacy Officer at (203) 432-5919. If you would like to talk with
someone other than the researchers to discuss problems, concerns, and questions you may
have concerning this research, or to discuss your rights as a research subject, you may
contact the Yale Human Investigation Committee at (203) 785-4688.

73

APPENDIX E: Sample Size Calculation

Group

Proportion
Positive

N Per
Group

No Marijuana Use

0.115

240

Marijuana Use

0.209

240

Rate Difference

-0.094

480

Standard
Error

95%
Lower

95%
Upper

0.033

-0.159

-0.029

Alpha = 0.050, Tails = 2, Power = 0.800
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